Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,928 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Pressure, High Clear all
Completed Not applicable Interventional Results available

Hydrus Microstent for Refractory Open-Angle Glaucoma

NCT03267134
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 2Phase 3 Interventional

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

NCT00851929
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 16, 2026, 3:40 AM EDT
Recruiting No phase listed Observational

Remote Fetal Monitoring in High Risk Pregnancies

NCT06822439
View directory record Official record
Conditions
High Risk Pregnancy, Remote Patient Monitoring, Diabetes, Hypertension
Interventions
Fetal ECG monitoring
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 16, 2026, 3:40 AM EDT
Withdrawn Phase 3 Interventional

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

NCT03508739
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
Interventions
Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 3:40 AM EDT
Active, not recruiting Phase 4 Interventional

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

NCT03581877
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions
Alteplase, EKOS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Bay Shore, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

NCT00779181
View directory record Official record
Conditions
Hypertension
Interventions
ADX415, Placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 16, 2026, 3:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Endoplasmic Reticulum Stress in Human Hypertension

NCT06025630
View directory record Official record
Conditions
Hypertension
Interventions
TUDCA, Placebo
Drug
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function

NCT00001628
View directory record Official record
Conditions
Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions
Angiotensin II type 1 receptor antagonists
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 3:40 AM EDT
Recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

NCT00549770
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 16, 2026, 3:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

NCT00710177
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 12 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 16, 2026, 3:40 AM EDT
Active, not recruiting Not applicable Interventional

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

NCT05925569
View directory record Official record
Conditions
Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension, Hyperaldosteronism, Mineralocorticoid Excess, Hypertension
Interventions
Best Practice Advisory Computerized Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
12,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 16, 2026, 3:40 AM EDT
Terminated Phase 2 Interventional

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524
View directory record Official record
Conditions
PAH
Interventions
75mg CXA-10, 150mg CXA-10, Placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 16, 2026, 3:40 AM EDT
Withdrawn Not applicable Interventional

Tailored Drug Titration Through Artificial Intelligence

NCT03397524
View directory record Official record
Conditions
Hypertension
Interventions
optima4BP
Other
Lead sponsor
Optima Integrated Health
Industry
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

NCT01896180
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
Interventions
ALZ-1101, Latanoprost
Drug
Lead sponsor
Alleanza Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Not applicable Interventional Results available

SDOCT-GMPE Software

NCT02235454
View directory record Official record
Conditions
Glaucoma
Interventions
SDOCT-GMPE software
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support

NCT02701829
View directory record Official record
Conditions
Improving Blood Pressure Control
Interventions
CONTROL- Usual & Customary Health Fair Follow-up, Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring], Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)

NCT00821002
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Latanoprost
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Not applicable Interventional Results available

The Support, Educate, Empower (SEE) Program

NCT04735653
View directory record Official record
Conditions
Glaucoma
Interventions
Personalized Glaucoma Coaching, Enhanced Standard care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 16, 2026, 3:40 AM EDT
Terminated Phase 4 Interventional Results available

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

NCT02053246
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Nebivolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 1 Interventional

Antibiotics, Gastric Bypass, and the Microbiome

NCT05367479
View directory record Official record
Conditions
Obesity, Morbid, Hypertension, Bariatric Surgery Candidate
Interventions
Antibiotic
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 16, 2026, 3:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Health Effects of Grain Foods in Adults

NCT06339879
View directory record Official record
Conditions
High Whole Grain and Low Sugar, Medium Whole Grain and Low Sugar, Low Whole Grain and Low Sugar, Low Whole Grain and High Sugar
Interventions
High Whole Grain, Low Sugar, Low Whole Grain, Low Sugar, High Whole Grain, High Sugar, Low Whole Grain, High Sugar
Other
Lead sponsor
Purdue University
Other
Eligibility
21 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

NCT01841762
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 16, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Nitrite in Subjects With Pulmonary Hypertension

NCT01431313
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure, Diastolic
Interventions
Inhaled Nitrite
Drug
Lead sponsor
Schmidhofer, Mark, MD
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 16, 2026, 3:40 AM EDT